Mayne Pharma GroupMAYNF 48 EBIT per Share is $-0.35 as of Dec. 2025. GuruFocus rates MAYNF with a GF Score™ of 48/100 and a GF Value™ of $3.87 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 106 Medical Distribution companies, Mayne Pharma Group ranks better than 72.64% on this metric.
Mayne Pharma Group's EBIT per Share for the
six
months ended in Dec. 2025 was $0.07.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.35.
During the past 3 years, the average EBIT per Share Growth Rate was 14.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Mayne Pharma Group's EBIT per Share or its related term are showing as below:
MAYNF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -106 Med: 18.55 Max: 63.8
Current: 14.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Mayne Pharma Group was 63.80% per year. The lowest was -106.00% per year. And the median was 18.55% per year.
MAYNF's 3-Year EBIT Growth Rate is ranked better than 72.64% of 106
companies
in the Medical Distribution industry
Industry Median: 4.1
vs MAYNF: 14.40
Mayne Pharma Group (OTCPK:MAYNF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Mayne Pharma Group EBIT per Share Related Terms
Mayne Pharma Group EBIT per Share Historical Data
* Premium members only.
The historical data trend for Mayne Pharma Group's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.35
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayne Pharma Group (MAYNF) has a EBIT per Share of $-0.35 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Mayne Pharma Group and its competitors. According to the industry distribution chart, Mayne Pharma Group ranks #29 out of 106 companies in the Medical Distribution industry, placing it in the top 27.4%.
Is Mayne Pharma Group's EBIT per Share too high?
Mayne Pharma Group's current EBIT per Share is $-0.35. Based on the distribution chart, Mayne Pharma Group ranks #29 out of 106 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Mayne Pharma Group has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's EBIT per Share compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #29 out of 106 companies for EBIT per Share. This puts Mayne Pharma Group in the upper half of its industry. The industry median EBIT per Share is 4.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Distribution company?
The median EBIT per Share among Medical Distribution companies is 4.10, based on 106 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Mayne Pharma Group and its competitors. For the Medical Distribution industry, the median EBIT per Share is 4.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current EBIT per Share is $-0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (MAYNF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.87, compared to a current price of $1.65 — trading 57.4% below its estimated fair value. The current EBIT per Share is $-0.35. Mayne Pharma Group's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Mayne Pharma Group (MAYNF), the current EBIT per Share is $-0.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayne Pharma Group (MAYNF) Overvalued in 2026?
Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued.
The current stock price of $1.65 is trading 57.4% below its estimated GF Value™ of $3.87.
GuruFocus considers Mayne Pharma Group to be Possible Value Trap.
Key valuation signals for MAYNF:
EBIT per Share: $-0.35
GF Value™: $3.87 vs. price of $1.65 (57.4% below fair value)
No single metric tells the full story. See the MAYNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
48GF Score
Get the complete analysis for MAYNF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAYNF has been successfully added to your 
